Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says

Analysts see the weight-loss drug market reaching at least $100 billion by the end of the decade, as consumers flock to Wegovy and Zepbound, which have been shown to reduce weight by as much as 20%, and other medicines in development. JPMorgan in a report last year said Gerresheimer makes injection pens to administer the drugs for Novo and Lilly. Gerresheimer confirmed that its dual-chamber syringe would be used by Novo Nordisk for its experimental obesity drug cagrisema, according to a Jefferies note from this month.

EU drug regulator to review Lilly's Mounjaro in multi-dose pen

The U.S. drugmaker won EU approval for the weekly injection late last year and has initially made starter doses available in member states Germany and Poland packaged in vials, so that patients need to draw the medication into syringes before injection.

Cardinal Health lowers medical unit profit forecast, shares fall

The medical unit, through which Cardinal Health makes and distributes company-branded medical, surgical and laboratory products, has been struggling with rising transportation and labor costs as well as global supply chain constr

Dr Reddy's pick up 6.5 per cent stake in Israeli biotech company Edity

The Hyderabad-based company informed the bourses that it has picked up 10,14,442 Preferred A-1 shares, equivalent to 6.46 per cent of Edity’s share capital on a fully diluted basis, for US$1.9715 per share, by way of conversion of SAFE (simple agreement for future equity).

Akums acquires new formulation facility in Baddi, Himachal Pradesh

The newly acquired facility, sprawling across approximately six acres, is currently undergoing upgrades and is slated to become operational in the year 2024. Once operational, it will serve as an OSD pharmaceutical formulation facility, significantly enhancing the company’s tablet manufacturing capacity.

Government approves 4 home-grown, cheaper drugs for rare diseases

while the annual cost of the imported Nitisinone capsule that is used in the treatment of Tyrosinemia Type 1 comes to Rs 2.2 crore, the domestically manufactured capsules will now be available for just Rs 2.5 lakh. Tyrosinemia Type 1 is a rare disease that affects one in a lakh population.

Enzene biosciences launches Ranibizumab to treat neovascular AMD

Pune-based Enzene Biosciences has launched the Ranibizumab the seventh biosimilar a recombinant Fab used as a treatment for neovascular age-related macular degeneration (AMD). The company further stated that ​ it is actively progressing with the development of three additional biosimilars in various stages.

First pill for dengue shows promise in human challenge trial

There are currently no specific treatments for dengue, a growing disease threat, the company said ahead of presentation of the data at the American Society of Tropical Medicine and Hygiene Annual Meeting in Chicago.

Biocon shares decline over 6 pc; mcap plunges Rs 1,896.95 crore

As per the USFDA, OAI implies that the regulator may withhold approval of any pending product applications or supplements filed from such facility till the outstanding observations related to non-compliance of manufacturing norms laid down by it.

OPPI appoints Anil Matai as Director-General

Matai comes with extensive experience in the Life Sciences space having worked across MNCs including spearheading operations across Novartis India Ltd, GSK India, and Global Pharma, Dubai.

OPPI appoints Anil Matai as Director-General

Matai comes with extensive experience in the Life Sciences space having worked across MNCs including spearheading operations across Novartis India Ltd, GSK India, and Global Pharma, Dubai.

BioNTech warns of write-off of up to 900 mln euros on COVID vaccine

Hit by a plunge in use of pandemic-related products, Pfizer on Friday said it would take $900 million in write-offs and other charges for their jointly developed Comirnaty vaccine, on top of much larger write-offs on Pfizer's own COVID treatment Paxlovid.

IPC officially joins as member of PDG

The inclusion of IP in PDG will significantly increase the visibility of the Indian Pharmacopoeia on the international platform. It will establish IP as progressive pharmacopoeia which designs drug quality standards at par with global standards. Application of these standards will lead to the production of world-class pharmaceutical products for domestic and export markets.

US drugmaker Bristol Myers Squibb buys Mirati for $4.8bn

Bristol Myers Squibb will pay $58 per share in cash "for a total equity value of $4.8 billion," the companies said in a joint statement. In addition, a guaranteed value certificate (GVC) could provide Mirati shareholders with a potential additional $12.00 per share, or up to an additional $1 billion in total.

IPA organises 8th Advanced Good Manufacturing Practices Workshop

The workshop served as a forum where manufacturers, regulators, and subject matter experts came together to engage in meaningful discussions and deliberate on strategies for advancing manufacturing and quality excellence within the pharmaceutical industry.

Strides Pharma gets USFDA nod to market HIV drug

The company's product is bioequivalent and therapeutically equivalent to Atripla Tablets of Gilead Sciences LLC, it added. As per per IQVIA, Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumurate tablet (EET) has a market opportunity of USD 7.5 million in the US.

BDR Pharmaceutical launches Zisavel capsules to treat invasive aspergillosis, mucormycosis

The product will be available in 100 mg capsules and is the first line of treatment for the aforementioned fungal infections. The price of the generic drug will be Rs 7992, for seven capsules which is one-third the cost of present therapy available by innovators.

Need for innovative treatment options for insomnia as Z-drugs show limitations: GlobalData

Z-drugs promote GABA neurotransmission, cognitive impairment, dependence, withdrawal symptoms, and falls due to imbalance are the common risks associated with long-term use of these drugs: Christie Wong

Malaria vaccine co-developed by Serum Institute will bridge supply gap: Adar Poonawalla

As malaria vaccine developed by the University of Oxford and the Serum Institute of India (SII) has been recommended for use by the World Health Organisation (WHO), SII chief Adar Poonawalla said that the combined efforts of both of them have come to fruition.

Granules ANDA for hypertension drug gets USFDA nod

Granules’ hypertension lowering drug is a generic version of Organon LLC’s reference listed drug (RLD) Hyzaar. Apart from lowering blood pressure the drug also reduces the risk of stoke in patients with hypertension and left ventricular hypertrophy.